Articles

Poll

Podcasts

Slideshows

Videos

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Norouzi reflects on significant advances in glomerular disease from Q1 and looks ahead to what the rest of 2025 may have to offer.

What’s New and What’s Next in Glomerular Disease Care, with Sayna Norouzi, MD

Kraus explains current unmet needs in IgA nephropathy and what sibeprenlimab may offer based on the phase 3 VISIONARY study.

Sibeprenlimab’s Potential in IgA Nephropathy, with John Kraus, MD, PhD

Lafayette reflects on recent therapeutic advances in IgA nephropathy and looks ahead to other renal pipeline developments he’s looking forward to in 2025.

Progress in IgAN and Future Innovations in Nephrology, with Richard Lafayette, MD

Lafayette describes ongoing unmet needs in IgAN care and how the growing understanding of disease pathogenesis has informed drug development.

Understanding Atrasentan (Vanrafia) for IgA Nephropathy, with Richard Lafayette, MD

Our Q1 recap for nephrology spotlights regulatory updates, new clinical trial data, and advancements in xenotransplant.

Q1 2025 Recap: Nephrology News and Updates

Our top 5 headlines featured key FDA moves in nephrology and ophthalmology, from new approvals to trial terminations and priority reviews.

The HCPFive: Top News for Healthcare Providers from the Week of 03/30

The approval indicates Novartis's atrasentan (Vanrafia) for proteinuria reduction in primary IgA nephropathy.

Atrasentan (Vanrafia) Receives Accelerated Approval in IgA Nephropathy

The March 2025 month in review spotlights a new episode of Crisis Point about CKD for National Kidney Month and renal FDA news.

Nephrology Month in Review: March 2025

The FDA accepted an sNDA for pegcetacoplan for C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis.

FDA Accepts Pegcetacoplan (Empaveli) sNDA for C3G, IC-MPGN

The Biologics License Application submission for sibeprenlimab is supported by results from the phase 2 ENVISION and phase 3 VISIONARY clinical trials.

Otsuka Files BLA for Sibeprenlimab for IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.